Ra Pharmaceuticals Inc.
Developing oral peptide-like drugs using synthetic amino acids
This article was originally published in Start Up
Ra Pharmaceuticals Inc. is developing and establishing a new class of drugs called Cyclomimetics. The just-out-of-stealth-mode biotech says these drugs will be orally available peptide therapeutics combining the diversity and specificity of antibodies with some of the benefits of small molecules, including oral dosing and longer half-lives. Its first drug program will pursue an oral kallikrein inhibitor for prevention of hereditary angioedema.